Annexin Pharmaceuticals

23,00 SEK

-2,54 %

Mindre end 1K følgere

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

-2,54 %

-13,53 %

-16,67 %

-33,72 %

-45,60 %

-48,90 %

-59,30 %

-73,81 %

-92,81 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Markedsværdi

162,36 mio. SEK

Aktieomsætning

32,68 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

5.2

2026

Årsrapport '25

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse5.12.2025, 07.30

First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals

Pressemeddelelse19.11.2025, 12.32

BioStock: Video from Annexin Pharmaceutical's presentation at BioStock Life Science Summit 2025

Annexin Pharmaceuticals

Pressemeddelelse28.10.2025, 10.47

Redeye: Annexin (Q3’25 Review) - Clinical study in focus

Annexin Pharmaceuticals

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse23.10.2025, 08.29

BioStock: Annexin's Q3: Establishment of Medical Advisory Board and focus on ophthalmology

Annexin Pharmaceuticals

Pressemeddelelse15.10.2025, 06.30

Annexin Pharmaceuticals selected to present at the Eyecelerator conference and meets with the Medical Advisory Board in Orlando

Annexin Pharmaceuticals

Pressemeddelelse18.9.2025, 06.25

BioStock: Annexin strengthens operations with Medical Advisory Board

Annexin Pharmaceuticals

Pressemeddelelse16.9.2025, 06.30

Annexin appoints world-leading ophthalmology experts to Medical Advisory Board

Annexin Pharmaceuticals

Pressemeddelelse13.8.2025, 08.55

BioStock: Annexin gets green light for phase IIa study in diabetic retinopathy

Annexin Pharmaceuticals

Pressemeddelelse7.8.2025, 06.30

Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals

Pressemeddelelse24.7.2025, 08.05

BioStock: Annexin's CEO comments on Q2

Annexin Pharmaceuticals

Pressemeddelelse21.7.2025, 06.25

Redeye: Annexin Q2 - Positioned to advance: DR study and BD efforts

Annexin Pharmaceuticals

Pressemeddelelse16.6.2025, 16.10

Annexin participates in several investor and industry events

Annexin Pharmaceuticals

Pressemeddelelse11.6.2025, 09.12

Redeye: Annexin Q1 - Positioned for dealmaking

Annexin Pharmaceuticals

Pressemeddelelse19.5.2025, 07.43

BioStock: Annexin summarizes Q1: promising study data and fully subscribed issue

Annexin Pharmaceuticals

Selskabsmeddelelse26.3.2025, 07.30

Annexin's rights issue 100 percent subscribed, top guarantee commitments included, and resolution on directed issue to guarantors

Annexin Pharmaceuticals

Pressemeddelelse7.3.2025, 07.30

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

Annexin Pharmaceuticals

Selskabsmeddelelse6.3.2025, 07.30

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals

Pressemeddelelse17.2.2025, 14.05

Annexin Pharmaceuticals AB: BioStock: Annexin confirms promising results and strengthens financial position

Annexin Pharmaceuticals

Pressemeddelelse6.2.2025, 15.00

Database lock completed in Annexin's Phase 2a study in RVO. Data confirms promising results – providing strong support for continued development of the drug candidate ANXV

Annexin Pharmaceuticals

Selskabsmeddelelse6.2.2025, 14.47

Annexin resolves on a rights issue of approximately SEK 50 million, secured to approximately 80 percent, subject to approval by the Extraordinary General Meeting

Annexin Pharmaceuticals

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.